Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Spondyloarthritis
•
General Rheumatology
What is your approach to the evaluation of a patient with persistent costochondritis?
Related Questions
In a patient with active spondylarthritis and uveitis who cannot take TNF inhibitors, what is your next agent of choice?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
Do you combine methotrexate and leflunomide for the treatment of RA?
In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?
What is your approach to differentiating and managing DMARD-induced nodulosis (induced by methotrexate or leflunomide for example) from "de novo" RA nodules in seropositive RA patients?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
